SubsidieMeestersIDEFIX Multiorgan toxicity and efficacy test platform
Cherry Biotech's IDEFIX project aims to revolutionize preclinical drug testing by developing a customizable organ-on-chip platform that mimics human multiorgan physiology, enhancing efficacy and toxicity predictions.
Projectdetails
Introduction
To address the critical problem of the failure of animal testing to predict drug effects (toxicity and efficacy) in humans, Cherry Biotech develops a breakthrough organ-on-chip/MPS solution based on microfluidic technology. Using human tissue, our IDEFIX technology mimics multiorgan physiology and physiopathology.
Objectives
Our MPS platform aims to be the new standard as an alternative to animal experimentation in preclinical studies. Indeed, our solution succeeds in tackling all major industry bottlenecks:
- Seamless adaptability to current workflows
- Compatibility with all standard multiwell cell cultures and tissues
- Full microenvironment control and measurement
- State-of-the-art reconstruction of complex tissues (vascularization, immune system, circulating metastasis, multiorgan interconnection)
Technology
This is now achievable by combining the patent-pending gas mixers technology (FR2109230, TRL-3 coming from H2020-FET-OPEN project ELECTROMED) with Cherry Biotech proprietary microfluidic technologies in gas enrichment and simultaneous liquid flow (EP3712244; FR3094012; US2020299631) and our unique know-how in tissue engineering.
Project Development
Within the Transition project, the IDEFIX demonstrator will be completed as a modular platform, with stackable modules (gas, flow, temperature, biosensing, microscopy & imaging control). This design allows users to customize the platform according to their respective needs and budget.
Qualification and Testing
The final qualification will be conducted in relevant environments, with two European pharmaceutical companies and a hospital/research center using vascularized liver, adipose, and breast cancer tissues. We will test our models to predict the efficacy and toxicity of various known molecules and compare them to previous preclinical animal experimentations and clinical results (retrospective study).
Expected Outcomes
By the end of this project, the IDEFIX demonstrator will reach TRL-6, be investment-ready/IRL-7, and be prepared for pre-commercialization to early adopters.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 2.496.073 |
| Totale projectbegroting | € 2.496.073 |
Tijdlijn
| Startdatum | 1-11-2022 |
| Einddatum | 31-8-2024 |
| Subsidiejaar | 2022 |
Partners & Locaties
Projectpartners
- CHERRY BIOTECHpenvoerder
Land(en)
Vergelijkbare projecten binnen EIC Transition
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Simultaneous Multiparametric MEA based platform for in-vitro chronic cardiotoxicity assessment with live-cell fluorescence imaging and electrophysiology.SiMulTox develops a novel platform for simultaneous long-term assessment of functional and structural cardiotoxicity, aiming to enhance drug safety evaluation and reshape the in-vitro testing market. | EIC Transition | € 786.875 | 2022 | Details |
Bringing 3D cardiac tissues to high throughput for drug discovery screensDeveloping a high-throughput 3D cardiac model using microfluidic technology to enhance drug discovery for cardiovascular disease by improving predictive accuracy and scalability. | EIC Transition | € 1.457.500 | 2023 | Details |
Simultaneous Multiparametric MEA based platform for in-vitro chronic cardiotoxicity assessment with live-cell fluorescence imaging and electrophysiology.
SiMulTox develops a novel platform for simultaneous long-term assessment of functional and structural cardiotoxicity, aiming to enhance drug safety evaluation and reshape the in-vitro testing market.
Bringing 3D cardiac tissues to high throughput for drug discovery screens
Developing a high-throughput 3D cardiac model using microfluidic technology to enhance drug discovery for cardiovascular disease by improving predictive accuracy and scalability.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Multi-organ toxicity and efficacy test platform for Personalized medicine & Drug developmentCherry Biotech aims to revolutionize drug development and personalized medicine by providing a patented 3D cell culture platform that enhances predictability and reduces reliance on animal testing. | EIC Accelerator | € 2.499.831 | 2024 | Details |
High Throughput Modelling and Measurement of Human Epithelial Models using Electrospun Conducting Polymers For Unlocking Data-Driven Drug DiscoveryThe project aims to enhance drug discovery by developing simplified Organ on Chip platforms through hydrogel electrospinning, enabling scalable monitoring and integration into industry workflows. | ERC Proof of... | € 150.000 | 2025 | Details |
High-throughput combinatory drugs testing on in vitro 3D cells model platformThe project aims to develop a microfluidic platform for high-throughput screening of drug combinations in 3D cultures to enhance drug discovery and identify synergistic therapies for breast cancer. | ERC Proof of... | € 150.000 | 2023 | Details |
Organ on a chip platform for drug discoveryBI/OND ontwikkelt innovatieve hardwareoplossingen voor organen op een chip om gepersonaliseerde medicijnen te bevorderen en het gebruik van dieren in pre-klinisch onderzoek te verminderen. | Mkb-innovati... | € 20.000 | 2021 | Details |
Platform for parallelized biological testsBI/OND ontwikkelt een gebruiksvriendelijke interface voor geautomatiseerde en parallelle tests met organ-on-a-chip technologie om gepersonaliseerde medicijnen te bevorderen en dierenproeven te verminderen. | Mkb-innovati... | € 20.000 | 2022 | Details |
Multi-organ toxicity and efficacy test platform for Personalized medicine & Drug development
Cherry Biotech aims to revolutionize drug development and personalized medicine by providing a patented 3D cell culture platform that enhances predictability and reduces reliance on animal testing.
High Throughput Modelling and Measurement of Human Epithelial Models using Electrospun Conducting Polymers For Unlocking Data-Driven Drug Discovery
The project aims to enhance drug discovery by developing simplified Organ on Chip platforms through hydrogel electrospinning, enabling scalable monitoring and integration into industry workflows.
High-throughput combinatory drugs testing on in vitro 3D cells model platform
The project aims to develop a microfluidic platform for high-throughput screening of drug combinations in 3D cultures to enhance drug discovery and identify synergistic therapies for breast cancer.
Organ on a chip platform for drug discovery
BI/OND ontwikkelt innovatieve hardwareoplossingen voor organen op een chip om gepersonaliseerde medicijnen te bevorderen en het gebruik van dieren in pre-klinisch onderzoek te verminderen.
Platform for parallelized biological tests
BI/OND ontwikkelt een gebruiksvriendelijke interface voor geautomatiseerde en parallelle tests met organ-on-a-chip technologie om gepersonaliseerde medicijnen te bevorderen en dierenproeven te verminderen.